Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.
This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...
After hours: 7 March at 7:59:57 pm GMT-5 Loading Chart for LLY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback